Role of the Environment and Endocrine Disruptors in Child Cryptorchidism

Recruiting Observational Study
Cryptorchidism
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Month – 18
Sex
Male
Study type
Observational
Participants needed
1,452 (estimated)
Sponsor
University Hospital, Montpellier · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: \- Parents of male children from the neonatal period to 18 years of age (during surgery) with cryptorchidism Exclusion criteria: * Parents of children without endocrine disease. (adrenal, hypothalamic-pituitary, phosphocalcic, thyroid, diabetes, etc.) * Parents of children wit…
Contacts

Nicolas KALFA, MD

00334 67 33 87 84

n-kalfa@chu-montpellier.fr

CONTACT